GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Precision BioSciences Inc (FRA:PBS0) » Definitions » Debt-to-Revenue

Precision BioSciences (FRA:PBS0) Debt-to-Revenue : 0.44 (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Precision BioSciences Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Precision BioSciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €21.75 Mil. Precision BioSciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €6.82 Mil. Precision BioSciences's annualized Revenue for the quarter that ended in Mar. 2024 was €64.71 Mil. Precision BioSciences's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 0.44.


Precision BioSciences Debt-to-Revenue Historical Data

The historical data trend for Precision BioSciences's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Precision BioSciences Debt-to-Revenue Chart

Precision BioSciences Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial - 0.43 0.08 0.99 0.64

Precision BioSciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.76 0.35 0.46 1.11 0.44

Competitive Comparison of Precision BioSciences's Debt-to-Revenue

For the Biotechnology subindustry, Precision BioSciences's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Precision BioSciences's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Precision BioSciences's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Precision BioSciences's Debt-to-Revenue falls into.



Precision BioSciences Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Precision BioSciences's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(21.591 + 7.082) / 44.683
=0.64

Precision BioSciences's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(21.751 + 6.818) / 64.708
=0.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.


Precision BioSciences Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Precision BioSciences's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Precision BioSciences (FRA:PBS0) Business Description

Traded in Other Exchanges
Address
302 East Pettigrew Street, Dibrell Building, Suite A-100, Durham, NC, USA, 27701
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.

Precision BioSciences (FRA:PBS0) Headlines

No Headlines